1、1This document contains proprietary information of Viatris Inc.Unauthorized use,duplication,dissemination or disclosure to third parties is strictly prohibited.2025 Viatris Inc.All Rights Reserved.VIATRIS and the Viatris Logo are trademarks of Mylan Inc.,a Viatris company.Q2 2025 EarningsAugust 7,20

2、252This document contains proprietary information of Viatris Inc.Unauthorized use,duplication,dissemination or disclosure to third parties is strictly prohibited.2025 Viatris Inc.All Rights Reserved.VIATRIS and the Viatris Logo are trademarks of Mylan Inc.,a Viatris company.Forward Looking Statement

3、sThis presentation contains“forward-looking statements”.These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.Such forward-looking statements may include,without limitation,statements about our 2025 financial guidance;2025 strategic

4、priorities,including drive strong execution,advance our pipeline,prioritize capital return with focus on share repurchases,target accretive regional business development,complete remediation for Indore facility and request reinspection,and conduct enterprise-wise strategic review;selatogrel and cene

5、rimod enrollment on track;Indore facility remediation nearly complete and in August will request an FDA meeting to discuss remediation progress and reinspection;strong progress on enterprise-wide strategic review and plan to provide update on Q3 2025 call;advancing 11 phase 3 programs,including stat

6、us and anticipated milestones;targeting new drug application submission to the U.S.FDA by the end of 2025 for Meloxicam(MR-107A-02);positive top-line read-outs in eye care phase 3 studies;VEGA-3 data expected to be presented at American Society of Cataract and Refractive Surgery(ASCRS)annual meeting